Jantje Weiskorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jantje Weiskorn has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Torben Biester
Department of Pediatric Diabetology, Children’s Hospital Auf der Bult, Hannover, Germany
7 shared publications - Felix Reschke
Centre for Diabetes and Endocrinology Children's Hospital Auf der Bult Hannover Germany
6 shared publications - Olga Kordonouri
Auf der Bult Children’s Hospital, Hannover, Germany
6 shared publications - Kerstin Kapitzke
Department of Pediatric Diabetology, Children’s Hospital Auf der Bult, Hannover, Germany
4 shared publications Mareike Niemeyer
Centre for Diabetology and Endocrinology, Children`s Hospital AUF DER BULT , Hannover , Germany
3 shared publications- Bart Van der Schueren
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- 10 November 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
The beneficial impact of a lifestyle modification program on childhood obesity: a comparative study of demographic, anthropometric, and social factors over a decade
Objectives: Juvenile obesity is a major risk factor for the development of type 2 diabetes. KiCK is a 1-year outpatient pediatric obesity therapy program at the AUF DER BULT Children’s and Youth Hospital. In addition to multiprofessional obesity training, clinical and laboratory data are collected at the beginning and end of the program, and a standardized 6-min walking test (6MWT) is carried out. Methods: BMI, laboratory parameters, daily media usage time, and the data of the 6-MWT of the program participants in the years 2009–2012 (“A”), 2012–2015 (“B”), and 2018–2019 (“C”) were recorded, and the differences between the three groups were analyzed. Results: Group A included n=64 children (mean age 12.0; 40.6 % female), group B included n=104 children (mean age 11.7; 55.8 % female), and group C included n=131 children (mean age 11.9; 58 % female). BMI-SDS improved constantly in all three groups (A: 2.4 vs. 2.3 (p=0.009); B: 2.4 vs. 2.2 (p=0.003); C: 2.4 vs. 2.1 (p=0.001)). Obesity therapy significantly improved the walking distance in group B in the 6-MWT (B: 574 m vs. 621 m (p=<0.001)). Conclusions: The significant improvement in BMI-SDS over decades shows the constant program’s contribution to improved weight outcomes in children and adolescents during the periods studied.
- 10 November 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
The beneficial impact of a lifestyle modification program on childhood obesity: a comparative study of demographic, anthropometric, and social factors over a decade
Objectives: Juvenile obesity is a major risk factor for the development of type 2 diabetes. KiCK is a 1-year outpatient pediatric obesity therapy program at the AUF DER BULT Children’s and Youth Hospital. In addition to multiprofessional obesity training, clinical and laboratory data are collected at the beginning and end of the program, and a standardized 6-min walking test (6MWT) is carried out. Methods: BMI, laboratory parameters, daily media usage time, and the data of the 6-MWT of the program participants in the years 2009–2012 (“A”), 2012–2015 (“B”), and 2018–2019 (“C”) were recorded, and the differences between the three groups were analyzed. Results: Group A included n=64 children (mean age 12.0; 40.6 % female), group B included n=104 children (mean age 11.7; 55.8 % female), and group C included n=131 children (mean age 11.9; 58 % female). BMI-SDS improved constantly in all three groups (A: 2.4 vs. 2.3 (p=0.009); B: 2.4 vs. 2.2 (p=0.003); C: 2.4 vs. 2.1 (p=0.001)). Obesity therapy significantly improved the walking distance in group B in the 6-MWT (B: 574 m vs. 621 m (p=<0.001)). Conclusions: The significant improvement in BMI-SDS over decades shows the constant program’s contribution to improved weight outcomes in children and adolescents during the periods studied.
- Open Access
- 14 October 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Performance of a 15-Day Continuous Glucose Monitoring System in Children and Adolescents With Diabetes
Background: The CareSens Air (CSAir) continuous glucose monitoring system is approved for use in adults in South Korea and received adults-only CE marking in early 2024. The aim of this prospective, multicenter, pivotal study in children and adolescents with insulin-dependent diabetes mellitus was to determine if the performance and safety of CSAir in these populations are comparable to those observed in adults. Method: Sensors were worn for 15 days on the upper arm in children and adolescents aged 7 to 17 years and on the upper arm and/or upper buttock in children aged 2 to 6 years. Frequent capillary comparator measurements were performed during in-clinic sessions at the beginning, middle, and end of the sensor-wearing period. Point accuracy was assessed via agreement rates (AR) and mean absolute relative difference (MARD). Additional assessments included clinical point accuracy, technical reliability, and safety. Results: For subjects aged 7 to 17 years, %20/20 AR was 90.8%, and MARD was 8.9%. A total of 99.9% of values fell within Zones A and B of the Diabetes Technology Society error grid. Sensor survival probability reached 75.2%. In children aged 2 to 6 years, %20/20 ARs were 86.6% and 98.4%, and MARDs were 10.3% and 7.8% for arm- and buttock-worn sensors, respectively. No serious adverse events were reported. Mild and moderate adverse device effects comprised skin issues such as itching or erythema at the sensor application or insertion site. Conclusions: The observed performance and safety of CSAir in children and adolescents are similar to those in adults. These data may support an extension of regulatory approval of CSAir for children aged 2 years and older.
- 14 October 2026
- Published by SAGE Publications in Journal of Diabetes Science and Technology
Open AccessPerformance of a 15-Day Continuous Glucose Monitoring System in Children and Adolescents With Diabetes
Background: The CareSens Air (CSAir) continuous glucose monitoring system is approved for use in adults in South Korea and received adults-only CE marking in early 2024. The aim of this prospective, multicenter, pivotal study in children and adolescents with insulin-dependent diabetes mellitus was to determine if the performance and safety of CSAir in these populations are comparable to those observed in adults. Method: Sensors were worn for 15 days on the upper arm in children and adolescents aged 7 to 17 years and on the upper arm and/or upper buttock in children aged 2 to 6 years. Frequent capillary comparator measurements were performed during in-clinic sessions at the beginning, middle, and end of the sensor-wearing period. Point accuracy was assessed via agreement rates (AR) and mean absolute relative difference (MARD). Additional assessments included clinical point accuracy, technical reliability, and safety. Results: For subjects aged 7 to 17 years, %20/20 AR was 90.8%, and MARD was 8.9%. A total of 99.9% of values fell within Zones A and B of the Diabetes Technology Society error grid. Sensor survival probability reached 75.2%. In children aged 2 to 6 years, %20/20 ARs were 86.6% and 98.4%, and MARDs were 10.3% and 7.8% for arm- and buttock-worn sensors, respectively. No serious adverse events were reported. Mild and moderate adverse device effects comprised skin issues such as itching or erythema at the sensor application or insertion site. Conclusions: The observed performance and safety of CSAir in children and adolescents are similar to those in adults. These data may support an extension of regulatory approval of CSAir for children aged 2 years and older.
- Open Access
- 18 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1) , 283
Subclinical cardiac involvement during diabetic ketoacidosis at type 1 diabetes onset in youth: biomarker elevation, altered diastolic filling, and reduced global longitudinal strain: a prospective cohort study
Background: Diabetic ketoacidosis (DKA) may be associated with cardiac involvement. Increased cardiac biomarkers and abnormalities in cardiac function were mainly reported in adults with type 1 diabetes (T1D). Pediatric data are lacking. This study therefore assessed cardiac biomarker alterations and echocardiographic changes, including strain analysis, in children with diabetic ketoacidosis at the onset of type 1 diabetes. Research design and methods: In this prospective, observational, cohort study, patients < 18 years with T1D onset were consecutively enrolled at a single center from January 2024 to March 2025 and classified as DKA or non-DKA. Cardiac biomarkers (troponin I, NT-proBNP) were measured before and 24 h after therapy initiation in all patients, and additionally at 48 and 72 h in those with DKA. Echocardiography, including speckle-tracking strain analysis, was performed after 24 h in both groups and after 6 days in the DKA group. Results: Eighty-one patients were included (60% male; median age 9.8 years [5.2–14.1]); 43 (53.1%) had DKA. Troponin I and NT-proBNP were significantly higher in the DKA group at baseline (troponin I: 5.7 [4.1–10.8] vs. 3.9 [3.9–4.6] ng/L, p < 0.001; NT-proBNP: 87.0 [41.0–231.0] vs. 40.0 [16.8–69.0] ng/L, p = 0.002) and remained elevated at 24 h. Echocardiography showed lower E/A ratios, higher peak a′-wave velocities, and a significantly reduced left ventricular global longitudinal strain (GLS) in the DKA group (− 19.2 [− 20.4 to − 18.1] vs. − 21.5 [− 23.0 to − 18.9], p = 0.029), with most values within the normal range. In multivariable analysis, lower bicarbonate (indicating greater DKA severity) was independently associated with higher troponin I and NT-proBNP, and younger age with higher NT-proBNP. Conclusions: In children with T1D, DKA at onset is associated with subclinical cardiac involvement, reflected by elevated cardiac biomarkers, altered diastolic filling parameters, and reduced left ventricular GLS. These findings indicate myocardial stress during the acute phase of DKA; whether they carry prognostic significance requires studies with longer-term follow-up. Trial registration: The study was registered in the German Clinical Trial Register (DRKS00032719).
- 18 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1) , 283
Open AccessSubclinical cardiac involvement during diabetic ketoacidosis at type 1 diabetes onset in youth: biomarker elevation, altered diastolic filling, and reduced global longitudinal strain: a prospective cohort study
Background: Diabetic ketoacidosis (DKA) may be associated with cardiac involvement. Increased cardiac biomarkers and abnormalities in cardiac function were mainly reported in adults with type 1 diabetes (T1D). Pediatric data are lacking. This study therefore assessed cardiac biomarker alterations and echocardiographic changes, including strain analysis, in children with diabetic ketoacidosis at the onset of type 1 diabetes. Research design and methods: In this prospective, observational, cohort study, patients < 18 years with T1D onset were consecutively enrolled at a single center from January 2024 to March 2025 and classified as DKA or non-DKA. Cardiac biomarkers (troponin I, NT-proBNP) were measured before and 24 h after therapy initiation in all patients, and additionally at 48 and 72 h in those with DKA. Echocardiography, including speckle-tracking strain analysis, was performed after 24 h in both groups and after 6 days in the DKA group. Results: Eighty-one patients were included (60% male; median age 9.8 years [5.2–14.1]); 43 (53.1%) had DKA. Troponin I and NT-proBNP were significantly higher in the DKA group at baseline (troponin I: 5.7 [4.1–10.8] vs. 3.9 [3.9–4.6] ng/L, p < 0.001; NT-proBNP: 87.0 [41.0–231.0] vs. 40.0 [16.8–69.0] ng/L, p = 0.002) and remained elevated at 24 h. Echocardiography showed lower E/A ratios, higher peak a′-wave velocities, and a significantly reduced left ventricular global longitudinal strain (GLS) in the DKA group (− 19.2 [− 20.4 to − 18.1] vs. − 21.5 [− 23.0 to − 18.9], p = 0.029), with most values within the normal range. In multivariable analysis, lower bicarbonate (indicating greater DKA severity) was independently associated with higher troponin I and NT-proBNP, and younger age with higher NT-proBNP. Conclusions: In children with T1D, DKA at onset is associated with subclinical cardiac involvement, reflected by elevated cardiac biomarkers, altered diastolic filling parameters, and reduced left ventricular GLS. These findings indicate myocardial stress during the acute phase of DKA; whether they carry prognostic significance requires studies with longer-term follow-up. Trial registration: The study was registered in the German Clinical Trial Register (DRKS00032719).
- 14 September 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (11) , 1172-1178
Clinical heterogeneity and disease progression during adolescence in AGPAT2-associated congenital generalized lipodystrophy: a case series of four patients
Objectives: This case series describes the clinical presentation and longitudinal course of four adolescents with genetically confirmed AGPAT2 -associated congenital generalized lipodystrophy (CGL) followed at a pediatric lipodystrophy center. Case presentation: Despite shared phenotypic features – including generalized lipoatrophy, muscular hypertrophy, acromegaloid features, and hyperphagia – metabolic severity varied markedly, even between siblings carrying the same homozygous AGPAT2 variant. All three female patients experienced rapid metabolic deterioration during puberty, developing insulin resistance, diabetes, and severe hypertriglyceridemia, while the male patient remained relatively metabolically stable. Three patients developed progressive albuminuria during adolescence, and two required ACE inhibitor therapy for hypertension, highlighting early renal involvement independent of diabetes. Metreleptin therapy led to substantial metabolic improvement in all treated patients, with normalization of glycemic control, triglyceride levels, and liver enzymes, as well as reduced hyperphagia and, in one case, spontaneous menarche. However, metabolic decompensation occurred during acute illness in one patient, necessitating treatment escalation, indicating that metreleptin does not fully protect against metabolic stress. Notably, pronounced daytime fatigue persisted in three patients despite metabolic stabilization, suggesting an underrecognized, potentially central component of the disease. Conclusions: These findings underscore the phenotypic variability of AGPAT2 -associated CGL, the critical impact of puberty – especially in females – the frequent early onset of nephropathy, and the partial but incomplete response to leptin replacement. Close monitoring during adolescence and individualized management are essential.
- 14 September 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (11) , 1172-1178
Clinical heterogeneity and disease progression during adolescence in AGPAT2-associated congenital generalized lipodystrophy: a case series of four patients
Objectives: This case series describes the clinical presentation and longitudinal course of four adolescents with genetically confirmed AGPAT2 -associated congenital generalized lipodystrophy (CGL) followed at a pediatric lipodystrophy center. Case presentation: Despite shared phenotypic features – including generalized lipoatrophy, muscular hypertrophy, acromegaloid features, and hyperphagia – metabolic severity varied markedly, even between siblings carrying the same homozygous AGPAT2 variant. All three female patients experienced rapid metabolic deterioration during puberty, developing insulin resistance, diabetes, and severe hypertriglyceridemia, while the male patient remained relatively metabolically stable. Three patients developed progressive albuminuria during adolescence, and two required ACE inhibitor therapy for hypertension, highlighting early renal involvement independent of diabetes. Metreleptin therapy led to substantial metabolic improvement in all treated patients, with normalization of glycemic control, triglyceride levels, and liver enzymes, as well as reduced hyperphagia and, in one case, spontaneous menarche. However, metabolic decompensation occurred during acute illness in one patient, necessitating treatment escalation, indicating that metreleptin does not fully protect against metabolic stress. Notably, pronounced daytime fatigue persisted in three patients despite metabolic stabilization, suggesting an underrecognized, potentially central component of the disease. Conclusions: These findings underscore the phenotypic variability of AGPAT2 -associated CGL, the critical impact of puberty – especially in females – the frequent early onset of nephropathy, and the partial but incomplete response to leptin replacement. Close monitoring during adolescence and individualized management are essential.
- 27 July 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (10) , 990-999
Menstrual cycle–related variations in insulin requirements and glycemic control during automated insulin delivery in adolescents with type 1 diabetes
Objectives: Data on menstrual cycle–related metabolic variability in adolescents with type 1 diabetes (T1D) using automated insulin delivery (AID) systems are scarce. We aimed to quantify cycle-dependent differences in insulin requirements and glycemic outcomes in this population. Methods: In this retrospective observational cohort study, adolescents with T1D aged 12.0–17.9 years who were at least 1 year postmenarche and had used AID for ≥6 months were included. Menstrual cycles were tracked using smartphone applications, and nine complete cycles per participant were analyzed. Insulin delivery and continuous glucose monitoring data were extracted from Glooko. Outcomes included total daily insulin dose (TDD), time in range (TIR), time above range (TAR), time below range (TBR), mean glucose, glucose coefficient of variation (CV), and recorded carbohydrate intake. Linear mixed-effects models were used. Results: Fifty-one adolescents contributed 459 menstrual cycles. Mean age was 14.7 ± 1.8 years, and median HbA 1c was 7.2 % (interquartile range 6.8–7.5 %). TDD was higher during the luteal than the follicular phase (1.05 vs. 0.95 U/kg/day; mean difference +0.10 U/kg/day, 95 % CI 0.05–0.15; p<0.001). The luteal phase was associated with reduced TIR (−6.3 %, p=0.001), increased TAR (+5.5 %, p=0.01), higher mean glucose (+12.5 mg/dL, p=0.03), and higher CV (39.4 vs. 35.0 %, p=0.03). TBR and carbohydrate intake did not differ significantly. Conclusions: In adolescents with T1D who menstruate and use AID systems, insulin requirements and glycemic control vary across the menstrual cycle, with increased insulin demand and hyperglycemia during the luteal phase. These findings highlight clinically relevant cycle-related metabolic variability despite the use of AID.
- 27 July 2026
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 39 (10) , 990-999
Menstrual cycle–related variations in insulin requirements and glycemic control during automated insulin delivery in adolescents with type 1 diabetes
Objectives: Data on menstrual cycle–related metabolic variability in adolescents with type 1 diabetes (T1D) using automated insulin delivery (AID) systems are scarce. We aimed to quantify cycle-dependent differences in insulin requirements and glycemic outcomes in this population. Methods: In this retrospective observational cohort study, adolescents with T1D aged 12.0–17.9 years who were at least 1 year postmenarche and had used AID for ≥6 months were included. Menstrual cycles were tracked using smartphone applications, and nine complete cycles per participant were analyzed. Insulin delivery and continuous glucose monitoring data were extracted from Glooko. Outcomes included total daily insulin dose (TDD), time in range (TIR), time above range (TAR), time below range (TBR), mean glucose, glucose coefficient of variation (CV), and recorded carbohydrate intake. Linear mixed-effects models were used. Results: Fifty-one adolescents contributed 459 menstrual cycles. Mean age was 14.7 ± 1.8 years, and median HbA 1c was 7.2 % (interquartile range 6.8–7.5 %). TDD was higher during the luteal than the follicular phase (1.05 vs. 0.95 U/kg/day; mean difference +0.10 U/kg/day, 95 % CI 0.05–0.15; p<0.001). The luteal phase was associated with reduced TIR (−6.3 %, p=0.001), increased TAR (+5.5 %, p=0.01), higher mean glucose (+12.5 mg/dL, p=0.03), and higher CV (39.4 vs. 35.0 %, p=0.03). TBR and carbohydrate intake did not differ significantly. Conclusions: In adolescents with T1D who menstruate and use AID systems, insulin requirements and glycemic control vary across the menstrual cycle, with increased insulin demand and hyperglycemia during the luteal phase. These findings highlight clinically relevant cycle-related metabolic variability despite the use of AID.
- Open Access
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
How Does Initiation of Continuous Glucose Monitoring Affect Weight and HbA1c Evolution in Adults Living With Type 1 Diabetes? An IMI2 SOPHIA Group-Based Multi-Trajectory Analysis
Background: To assess changes in HbA1c and weight over time after continuous glucose monitoring (CGM) initiation in adults with type 1 diabetes (T1D). Methods: Retrospective data from 4178 adults with T1D using CGM in Western Europe were analyzed. To assess changes in weight and HbA1c over 24 months after CGM initiation, paired t-tests and group-based multi-trajectory modeling were used. Findings : After 24 months of CGM initiation, a mean weight gain of 1.8kg±5.1 (p<0.0001) and 1.0kg±4.6 (p<0.0001) with a decrease in HbA1c of -1.7±10.7 mmol/mol (-0.2%±1.0; p<0.0001) and -0.7±8.9 mmol/mol (-0.1%±0.8; p<0.0001) were seen in the diabetes registry (DPV) (n=2104) and in the FUTURE/RESCUE (BE) cohort (n=2074), respectively. Three distinct bi-variate trajectories were identified in both cohorts: some weight gain with HbA1c decrease (DPV: 7.0% of cohort, weight +3.8kg, HbA1c -2.3%; BE: 20.5% of cohort, weight +1.3kg, HbA1c -1.1%), stable weight and HbA1c (DPV: 83.2%, weight +0.59kg, HbA1c-0.01%; BE: 68.1%, weight -0.27kg, HbA1c+0.2%), and weight gain with stable HbA1c (DPV: 9.9%, weight +11.1kg, HbA1c +0.01%; BE: 11.4%, weight +8.2kg, HbA1c -0.01%). Interpretation: CGM initiation resulted in a modest weight increase and HbA1c decrease. However, 10% of individuals experienced notable weight gain despite stable HbA1c, underscoring the persistent unmet need for additional strategies to avoid weight gain and improve glucose control.
- 25 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHow Does Initiation of Continuous Glucose Monitoring Affect Weight and HbA1c Evolution in Adults Living With Type 1 Diabetes? An IMI2 SOPHIA Group-Based Multi-Trajectory Analysis
Background: To assess changes in HbA1c and weight over time after continuous glucose monitoring (CGM) initiation in adults with type 1 diabetes (T1D). Methods: Retrospective data from 4178 adults with T1D using CGM in Western Europe were analyzed. To assess changes in weight and HbA1c over 24 months after CGM initiation, paired t-tests and group-based multi-trajectory modeling were used. Findings : After 24 months of CGM initiation, a mean weight gain of 1.8kg±5.1 (p<0.0001) and 1.0kg±4.6 (p<0.0001) with a decrease in HbA1c of -1.7±10.7 mmol/mol (-0.2%±1.0; p<0.0001) and -0.7±8.9 mmol/mol (-0.1%±0.8; p<0.0001) were seen in the diabetes registry (DPV) (n=2104) and in the FUTURE/RESCUE (BE) cohort (n=2074), respectively. Three distinct bi-variate trajectories were identified in both cohorts: some weight gain with HbA1c decrease (DPV: 7.0% of cohort, weight +3.8kg, HbA1c -2.3%; BE: 20.5% of cohort, weight +1.3kg, HbA1c -1.1%), stable weight and HbA1c (DPV: 83.2%, weight +0.59kg, HbA1c-0.01%; BE: 68.1%, weight -0.27kg, HbA1c+0.2%), and weight gain with stable HbA1c (DPV: 9.9%, weight +11.1kg, HbA1c +0.01%; BE: 11.4%, weight +8.2kg, HbA1c -0.01%). Interpretation: CGM initiation resulted in a modest weight increase and HbA1c decrease. However, 10% of individuals experienced notable weight gain despite stable HbA1c, underscoring the persistent unmet need for additional strategies to avoid weight gain and improve glucose control.
- 17 March 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (5) , 755-762
Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?
OBJECTIVE: We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values. RESEARCH DESIGN AND METHODS: A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age 2.6, >3.4, and >4.1 mmol/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4. RESULTS: The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL >3.4 mmol/L and >4.1 mmol/L, respectively. The parameters HbA1c (β = 1,142.7; P = 0.001), female sex (β = 861.5; P < 0.001), and BMI >70th percentile (β = 520.1; P < 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL >3.4 mmol/L and 87.0% with LDL >4.1 mmol/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4–23.7) for LDL >4.1 mmol/L; 3.1 (1.82–5.41) for ages 12–18 years; 2.31 (1.9–2.1) for diabetes duration of 5–10 years; 1.8 (1.5–2.1) for BMI >70th percentile; 1.3 (1.0–1.6) for HbA1c >9%; and 1.18 (1.0–1.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of 3.4 mmol/L. CONCLUSIONS: We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.
- 17 March 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (5) , 755-762
Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?
OBJECTIVE: We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values. RESEARCH DESIGN AND METHODS: A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age 2.6, >3.4, and >4.1 mmol/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4. RESULTS: The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL >3.4 mmol/L and >4.1 mmol/L, respectively. The parameters HbA1c (β = 1,142.7; P = 0.001), female sex (β = 861.5; P < 0.001), and BMI >70th percentile (β = 520.1; P < 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL >3.4 mmol/L and 87.0% with LDL >4.1 mmol/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4–23.7) for LDL >4.1 mmol/L; 3.1 (1.82–5.41) for ages 12–18 years; 2.31 (1.9–2.1) for diabetes duration of 5–10 years; 1.8 (1.5–2.1) for BMI >70th percentile; 1.3 (1.0–1.6) for HbA1c >9%; and 1.18 (1.0–1.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of 3.4 mmol/L. CONCLUSIONS: We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.
- 16 November 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (3) , 886-893
What is the Relationship Between Time in Range, Time in Tight Range, and HbA1c in Youth and Young Adults With Type 1 Diabetes? Results From the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-Up Registry
Objectives: Time in range (TIR, 70-180 mg/dL) is an established marker of glycemic control. More recently, time in tight range (TTR, 70-140 mg/dL) has been proposed as well. The aim of this study was to examine the relationship between TIR, TTR, and HbA1c in youth and young adults with type 1 diabetes (T1D) in the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-up (DPV) registry. Methods: Data of youth and young adults aged ≤25 years with T1D for >3 months, documented in the DPV registry between 2019 and 2022 were analyzed. The most recent available HbA1c and corresponding continuous glucose monitoring (CGM) profiles in the 12 preceding weeks with at least 80% completeness were included. Associations were investigated using correlation and adjusted regression models. Results: 1901 individuals (median age 14.0 years [IQR 10.4-16.9]) were included in the analysis. TIR and TTR correlated strongly, r = 0.965 (95% CI [0.962, 0.968]), P < .001. TTR estimates predicted from TIR were significantly higher in the group with high coefficient of variation (CV group ≥ 36%), P < .001. Correlations between TIR or TTR and HbA1c were both strong, r = −0.764 (95% CI [−0.782, −0.745]) and r = −0.777 (95% CI [−0.795, −0.759]), both P < .001, with no significant difference ( P = .312) However, adjusted regression models indicated a slightly better fit for the prediction of HbA1c from TIR compared with TTR. Conclusions: Based on large, real-world data from a multinational registry, TIR and TTR correlated strongly, and both showed a good prediction of HbA1c. TTR estimates predicted from TIR were significantly higher in people with high glucose variability (CV).
- 16 November 2024
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (3) , 886-893
What is the Relationship Between Time in Range, Time in Tight Range, and HbA1c in Youth and Young Adults With Type 1 Diabetes? Results From the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-Up Registry
Objectives: Time in range (TIR, 70-180 mg/dL) is an established marker of glycemic control. More recently, time in tight range (TTR, 70-140 mg/dL) has been proposed as well. The aim of this study was to examine the relationship between TIR, TTR, and HbA1c in youth and young adults with type 1 diabetes (T1D) in the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-up (DPV) registry. Methods: Data of youth and young adults aged ≤25 years with T1D for >3 months, documented in the DPV registry between 2019 and 2022 were analyzed. The most recent available HbA1c and corresponding continuous glucose monitoring (CGM) profiles in the 12 preceding weeks with at least 80% completeness were included. Associations were investigated using correlation and adjusted regression models. Results: 1901 individuals (median age 14.0 years [IQR 10.4-16.9]) were included in the analysis. TIR and TTR correlated strongly, r = 0.965 (95% CI [0.962, 0.968]), P < .001. TTR estimates predicted from TIR were significantly higher in the group with high coefficient of variation (CV group ≥ 36%), P < .001. Correlations between TIR or TTR and HbA1c were both strong, r = −0.764 (95% CI [−0.782, −0.745]) and r = −0.777 (95% CI [−0.795, −0.759]), both P < .001, with no significant difference ( P = .312) However, adjusted regression models indicated a slightly better fit for the prediction of HbA1c from TIR compared with TTR. Conclusions: Based on large, real-world data from a multinational registry, TIR and TTR correlated strongly, and both showed a good prediction of HbA1c. TTR estimates predicted from TIR were significantly higher in people with high glucose variability (CV).
- Open Access
- 1 November 2024
- Published by Bioscientifica in Endocrine Connections
- Vol. 13 (11)
ERRATUM: Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity
"ERRATUM: Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity" published on 01 Nov 2024 by Bioscientifica Ltd.
- 1 November 2024
- Published by Bioscientifica in Endocrine Connections
- Vol. 13 (11)
Open AccessERRATUM: Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity
"ERRATUM: Pediatric obesity and skin disease: cutaneous findings and associated quality-of-life impairments in 103 children and adolescents with obesity" published on 01 Nov 2024 by Bioscientifica Ltd.